Bradley Merrill Thompson, Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in multiple publications regarding the FTC’s action to pursue charges against various mobile apps due to unsubstantiated marketing claims and the FDA’s silence on the issue.
Following is an excerpt from HealthData Management:
Bradley Merrill Thompson, an attorney at Washington, D.C.-based law firm Epstein Becker Green who counsels medical device companies on regulatory issues, observes that as of late the U.S. Food and Drug Administration appears to be deferring to the FTC when it comes to medical claims about mobile apps.
“In this particular case, to me it seems relatively clear that the app is a medical device, and yet FTC still took the lead,” Thompson told Health Data Management. “Indeed, these can be very high risk apps. I agree that FTC has the right to enforcement, but the silence from FDA is somewhat deafening.”
Related reading:
FierceMobileHealthcare, 02/24/2015
HealthData Management, 02/24/2015
iHealthBeat, 02/24/2015
MobiHealthNews, 02/23/2015
